Bracco is a world-renowned medical group. Founded in Italy in 1927, Bracco has been operating in more than 100 markets worldwide, with more than 3,450 employees and annual revenue of more than 1.3 billion euros, about 87% of which comes from overseas markets outside Italy. The group invests nearly 10% of its annual net sales in research and development (imaging diagnosis and medical devices) and owns more than 1,800 patents. Bracco group is headquartered in Milan, Italy. Bracco group is consisted of three entites - the Bracco imaging diagnosis company (diagnostic imaging), Bracco medical system (medical devices and high-end contrast agent injection system), and the Italian diagnostic center specializing in clinical diagnosis.

Bracco imaging diagnostics is an original research and development company whose success has witnessed the history of the entire imaging industry. The company's unique products, covering radiation, CT, nuclear magnetic resonance, ultrasound and nuclear medicine and other fields. In 2001, Bracco group acquired ACIST, which provides high-quality medical devices and high-end contrast injection systems for the field of radiation and radiotherapy. ACIST is headquartered in Minneapolis and has offices in Europe and Asia. The advanced equipment of ACIST has been adopted by well-known medical centers in more than 40 countries, benefiting tens of millions of patients worldwide in cardiovascular angiography.

In addition, the group has opened an advanced polyclinic in Milan, the Italian diagnostic center (CDI), which provides services directly to patients for more than 30 years. The ambulatory center offers a full range of preventive, diagnostic, rehabilitation and personalized services, with a particular focus on radiosurgery and same-day surgery.  

Bracco has always been attaching importance to its development in China and looking forward to growing with China.

Bracco entered China in 1988 and set up its first office in Beijing in 2000. Shanghai Bracco Sine Pharmaceutical Corp. Ltd. was set up in 2001 (Bracco held 70% of the shares and Sine held 30% of the shares).

Its shareholder Sine is a subsidiary under the direct control of Shanghai Pharmaceuticals Group. Founded in 1916 and after over a hundred years of inheritance, Sine owns nine major industrial production bases, four major commercial companies, one municipal-level R&D center, and its marketing network extends to 10,000 hospitals in China. And Shanghai Pharmaceuticals Group is the No. 2 pharmaceutical enterprise in China, which is among the Top 500 enterprises in China. Bracco Sine set up a factory in Shanghai in 2002, and since then, the all-round pattern of Bracco Sine from production, business operation and medical support has been formed.